Patents by Inventor Jose S. Mendoza

Jose S. Mendoza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrazoles as heat shock transcription factor activators
    Patent number: 9717709
    Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: August 1, 2017
    Assignees: DUKE UNIVERSITY, CHAPERONE THERAPEUTICS, INC.
    Inventors: Dennis J. Thiele, Daniel W. Neef, Jose S. Mendoza
  • COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF
    Publication number: 20170000768
    Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.
    Type: Application
    Filed: September 19, 2016
    Publication date: January 5, 2017
    Inventors: Dennis J. Thiele, Daniel W. Neef, Jose S. Mendoza
  • Substituted 1,3-thiazoles as heat shock transcription factor 1 activators
    Patent number: 9447058
    Abstract: The present invention relates to 1,3-thiazole compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: September 20, 2016
    Assignees: Duke University, Chaperone Therapeutics, Inc.
    Inventors: Dennis J. Thiele, Daniel W. Neef, Jose S. Mendoza
  • Substituted pyrazoles as heat shock transcription factor activators
    Patent number: 9315449
    Abstract: The present invention relates to substituted pyrazole compounds, methods for their discovery, and their research and therapeutic uses, and pharmaceutical Formulations thereof. In particular, the present invention provides substituted pyrazole compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: April 19, 2016
    Assignees: DUKE UNIVERSITY, CHAPERONE THERAPEUTICS, INC
    Inventors: Dennis J Thiele, Daniel W Neef, Jose S Mendoza
  • COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF
    Publication number: 20160024035
    Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.
    Type: Application
    Filed: October 8, 2015
    Publication date: January 28, 2016
    Inventors: Dennis J. Thiele, Daniel W. Neef, Jose S. Mendoza
  • Substituted 1,3-thiazoles as heat shock transcription factor 1 activators
    Patent number: 9156775
    Abstract: The present invention relates to 1,3-thiazole compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: October 13, 2015
    Assignees: DUKE UNIVERSITY, CHAPERONE THERAPEUTICS, INC.
    Inventors: Dennis J. Thiele, Daniel W. Neef, Jose S. Mendoza
  • COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF
    Publication number: 20130267543
    Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.
    Type: Application
    Filed: November 8, 2011
    Publication date: October 10, 2013
    Applicants: CHAPERONE THERAPEUTICS, INC., DUKE UNIVERSITY
    Inventors: Dennis J. Thiele, Daniel W. Neef, Jose S. Mendoza
  • COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF
    Publication number: 20110112073
    Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.
    Type: Application
    Filed: November 12, 2010
    Publication date: May 12, 2011
    Applicant: DUKE UNIVERSITY
    Inventors: Dennis J. Thiele, Daniel W. Neef, Jose S. Mendoza
  • Indane derivatives for antipsychotic compositions
    Patent number: 6429317
    Abstract: The present invention provides novel indane-like compounds which can be useful for treating psychosis and other conditions associated with the modulation of a muscarinic receptor. The invention provides formulations and methods for using the novel compounds.
    Type: Grant
    Filed: September 5, 2000
    Date of Patent: August 6, 2002
    Assignee: Eli Lilly and Company
    Inventors: Sean P. Hollinshead, Michael A. Staszak, John S. Ward, Joseph W. Wilson, Bret E. Huff, Philip F. Hughes, Jose S. Mendoza, Charles H. Mitch
  • Potassium channel inhibitors
    Patent number: 6395730
    Abstract: Certain thiazolidinone and metathiazanone compounds, as described, are useful as potassium channel inhibitors and are especially useful for the treatment of cardiac arrhythmias and other diseases, conditions and disorders.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: May 28, 2002
    Assignees: Icagen, Inc., Eli Lilly and Company
    Inventors: Michael F. Gross, Neil A. Castle, Jose S. Mendoza
  • Potassium channel inhibitors
    Patent number: 6174908
    Abstract: Certain thiazolidinone and metathiazanone compounds, as described, are useful as potassium channel inhibitors and are especially useful for the treatment of cardiac arrhythmias and other diseases, conditions and disorders.
    Type: Grant
    Filed: May 1, 1999
    Date of Patent: January 16, 2001
    Assignees: ICAGen, Inc., Eli Lilly & Company Lilly Corporate Center
    Inventors: Michael F. Gross, Neil A. Castle, Jose S. Mendoza
  • Substituted fused and bridged bicyclic compounds as therapeutic agents
    Patent number: 5583221
    Abstract: Compounds having the formula ##STR1## methods for using such compounds to inhibit protein kinase C in animals, including man are useful as inhibitors of protein kinase C. Also disclosed are pharmaceutical compositions including such compounds and compounds having the formula.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: December 10, 1996
    Assignee: Eli Lilly and Company
    Inventors: Hong Hu, G. Erik Jagdmann, Jr., Jose S. Mendoza
  • Reaction vessel for combining chemicals
    Patent number: D414271
    Type: Grant
    Filed: February 3, 1997
    Date of Patent: September 21, 1999
    Assignee: Eli Lilly and Company
    Inventor: Jose S. Mendoza